vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $151.1M, roughly 1.2× STURM RUGER & CO INC). On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 3.6%). AMICUS THERAPEUTICS, INC. produced more free cash flow last quarter ($16.0M vs $12.3M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 5.1%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
FOLD vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $151.1M |
| Net Profit | $1.7M | — |
| Gross Margin | 85.7% | 17.8% |
| Operating Margin | 8.6% | 2.3% |
| Net Margin | 0.9% | — |
| Revenue YoY | 23.7% | 3.6% |
| Net Profit YoY | -88.5% | — |
| EPS (diluted) | $0.00 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.2M | $151.1M | ||
| Q3 25 | $169.1M | $126.8M | ||
| Q2 25 | $154.7M | $132.5M | ||
| Q1 25 | $125.2M | $135.7M | ||
| Q4 24 | $149.7M | $145.8M | ||
| Q3 24 | $141.5M | $122.3M | ||
| Q2 24 | $126.7M | $130.8M | ||
| Q1 24 | $110.4M | $136.8M |
| Q4 25 | $1.7M | — | ||
| Q3 25 | $17.3M | $1.6M | ||
| Q2 25 | $-24.4M | $-17.2M | ||
| Q1 25 | $-21.7M | $7.8M | ||
| Q4 24 | $14.7M | — | ||
| Q3 24 | $-6.7M | $4.7M | ||
| Q2 24 | $-15.7M | $8.3M | ||
| Q1 24 | $-48.4M | $7.1M |
| Q4 25 | 85.7% | 17.8% | ||
| Q3 25 | 88.5% | 15.1% | ||
| Q2 25 | 90.2% | 3.9% | ||
| Q1 25 | 90.7% | 22.0% | ||
| Q4 24 | 90.1% | 22.8% | ||
| Q3 24 | 90.6% | 18.5% | ||
| Q2 24 | 91.1% | 22.3% | ||
| Q1 24 | 87.7% | 21.5% |
| Q4 25 | 8.6% | 2.3% | ||
| Q3 25 | 20.3% | -2.7% | ||
| Q2 25 | -6.1% | -15.6% | ||
| Q1 25 | -6.3% | 6.2% | ||
| Q4 24 | 10.7% | 7.8% | ||
| Q3 24 | 15.3% | 3.1% | ||
| Q2 24 | 11.8% | 6.9% | ||
| Q1 24 | -25.1% | 5.5% |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 10.2% | 1.2% | ||
| Q2 25 | -15.8% | -13.0% | ||
| Q1 25 | -17.3% | 5.7% | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | -4.8% | 3.9% | ||
| Q2 24 | -12.4% | 6.3% | ||
| Q1 24 | -43.9% | 5.2% |
| Q4 25 | $0.00 | $0.22 | ||
| Q3 25 | $0.06 | $0.10 | ||
| Q2 25 | $-0.08 | $-1.05 | ||
| Q1 25 | $-0.07 | $0.46 | ||
| Q4 24 | $0.05 | $0.62 | ||
| Q3 24 | $-0.02 | $0.28 | ||
| Q2 24 | $-0.05 | $0.47 | ||
| Q1 24 | $-0.16 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $92.5M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $283.8M |
| Total Assets | $949.9M | $342.0M |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.5M | $92.5M | ||
| Q3 25 | $263.8M | $80.8M | ||
| Q2 25 | $231.0M | $101.4M | ||
| Q1 25 | $250.6M | $108.3M | ||
| Q4 24 | $249.9M | $105.5M | ||
| Q3 24 | $249.8M | $96.0M | ||
| Q2 24 | $260.1M | $105.6M | ||
| Q1 24 | $239.6M | $115.3M |
| Q4 25 | $392.7M | — | ||
| Q3 25 | $392.0M | — | ||
| Q2 25 | $391.3M | — | ||
| Q1 25 | $390.7M | — | ||
| Q4 24 | $390.1M | — | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — | ||
| Q1 24 | $388.4M | — |
| Q4 25 | $274.2M | $283.8M | ||
| Q3 25 | $230.4M | $279.6M | ||
| Q2 25 | $204.3M | $289.3M | ||
| Q1 25 | $193.6M | $321.5M | ||
| Q4 24 | $194.0M | $319.6M | ||
| Q3 24 | $178.8M | $314.9M | ||
| Q2 24 | $132.5M | $321.5M | ||
| Q1 24 | $130.7M | $332.0M |
| Q4 25 | $949.9M | $342.0M | ||
| Q3 25 | $868.8M | $342.3M | ||
| Q2 25 | $815.3M | $349.5M | ||
| Q1 25 | $789.8M | $379.0M | ||
| Q4 24 | $785.0M | $384.0M | ||
| Q3 24 | $786.6M | $373.5M | ||
| Q2 24 | $749.5M | $376.7M | ||
| Q1 24 | $721.8M | $385.0M |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — | ||
| Q1 24 | 2.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $15.5M |
| Free Cash FlowOCF − Capex | $16.0M | $12.3M |
| FCF MarginFCF / Revenue | 8.6% | 8.2% |
| Capex IntensityCapex / Revenue | 0.2% | 2.1% |
| Cash ConversionOCF / Net Profit | 9.62× | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $15.5M | ||
| Q3 25 | $35.7M | $12.9M | ||
| Q2 25 | $-26.5M | $14.7M | ||
| Q1 25 | $7.8M | $11.1M | ||
| Q4 24 | $-3.9M | $20.0M | ||
| Q3 24 | $-23.0M | $9.4M | ||
| Q2 24 | $22.7M | $18.7M | ||
| Q1 24 | $-29.7M | $7.3M |
| Q4 25 | $16.0M | $12.3M | ||
| Q3 25 | $35.3M | $7.0M | ||
| Q2 25 | $-28.9M | $9.1M | ||
| Q1 25 | $7.5M | $10.0M | ||
| Q4 24 | $-4.2M | $16.4M | ||
| Q3 24 | $-23.3M | $2.6M | ||
| Q2 24 | $21.6M | $10.1M | ||
| Q1 24 | $-31.5M | $5.6M |
| Q4 25 | 8.6% | 8.2% | ||
| Q3 25 | 20.9% | 5.5% | ||
| Q2 25 | -18.7% | 6.9% | ||
| Q1 25 | 6.0% | 7.4% | ||
| Q4 24 | -2.8% | 11.2% | ||
| Q3 24 | -16.5% | 2.1% | ||
| Q2 24 | 17.0% | 7.7% | ||
| Q1 24 | -28.5% | 4.1% |
| Q4 25 | 0.2% | 2.1% | ||
| Q3 25 | 0.2% | 4.6% | ||
| Q2 25 | 1.6% | 4.2% | ||
| Q1 25 | 0.2% | 0.8% | ||
| Q4 24 | 0.2% | 2.5% | ||
| Q3 24 | 0.3% | 5.5% | ||
| Q2 24 | 0.9% | 6.6% | ||
| Q1 24 | 1.6% | 1.3% |
| Q4 25 | 9.62× | — | ||
| Q3 25 | 2.06× | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | -0.27× | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
